Asset profile
fluticasone propionate
Small molecule
Evidence outlook
Approved: Asthma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
80 competitors in this universe: 9 direct rivals (same mechanism and indication), 11 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fluticasone Propionate: this drug | Approved | Small molecule | Glucocorticoid receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | ||
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor | ||
| Fluticasone Furoate | Approved | Small molecule | Glucocorticoid receptor | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Fluticasone Furoate / Vilanterol | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved | Combination | Glucocorticoid receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Lodotra (Rayos) | Approved | — | Glucocorticoid receptor | ||
| Ciclesonide (XRP1526) | Phase 3 | Small molecule | Glucocorticoid receptor | ||
| Budesonide (Entocort EC) | Approved | — | Glucocorticoid receptor | ||
| Budesonide (Ortikos) | Approved | — | Glucocorticoid receptor | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Budesonide (Uceris Rectal Foam) | Approved | — | Glucocorticoid receptor | ||
| Budesonide MMX (Uceris) | Approved | — | Glucocorticoid receptor | ||
| Halobetasol Propionate Foam (Lexette) | Approved | Small molecule | Glucocorticoid receptor |
…and 65 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (6)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (2)
What to watch
What to watch
September 2027 (1)
What to watch
December 2027 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.